Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients (Acclaim-3)
Condition: Small Cell Lung Cancer Extensive Stage Interventions: Biological: quaratusugene ozeplasmid; Biological: atezolizumab Sponsor: Genprex, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials